<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04763031</url>
  </required_header>
  <id_info>
    <org_study_id>PMC-3422401</org_study_id>
    <nct_id>NCT04763031</nct_id>
  </id_info>
  <brief_title>Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT</brief_title>
  <official_title>A Pilot Study of Patients With Recurrent Glioblastoma Treated With Maximal Safe Neurosurgical Resection, Intra-Operative Radiation Therapy (IORT) Using the Xoft® Axxent® Electronic Brachytherapy System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Parkridge Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Parkridge Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of the Xoft Axxent eBx System&#xD;
      when used for single-fraction IORT for recurrent Glioblastoma. IORT using the Xoft Axxent eBx&#xD;
      System is no worse than (non-inferior) GliaSite radiation therapy when used as stand-alone&#xD;
      radiation treatment immediately following maximal safe neurosurgical resection in patients&#xD;
      with recurrent glioblastoma multiforme (GBM).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Device Description: The Xoft Axxent Electronic Brachytherapy System is a device that delivers&#xD;
      radiation at a high dose rate. It is designed for use with Axxent applicators to treat&#xD;
      lesions, tumors, and conditions in or on the body where radiation is indicated. The Axxent&#xD;
      System and Applicators are FDA cleared under 510(k)s K050843, K072683, K090914 and K122951.&#xD;
&#xD;
      The purpose of this trial is to assess the overall survival of patients treated with the Xoft&#xD;
      Axxent eBx System for single-fraction IORT following maximal neurosurgical resection of&#xD;
      recurrent glioblastoma. A historical comparison will be made for surgical excision and&#xD;
      GliaSite radiation therapy (Chan 2005), which resulted in a median OS of 9.1 months.&#xD;
&#xD;
      Radiation is delivered to the target tissue (adjacent to the resection margins). It avoids&#xD;
      treatment delays and eliminates weeks of post-surgical radiation therapy during which&#xD;
      residual cancer cells might proliferate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 22, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single 20 Gy (gray) dose of electronic brachytherapy (IORT)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is Overall Survival (OS)</measure>
    <time_frame>Overall Survival (OS) will be defined as the interval from enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to three years.</time_frame>
    <description>The primary study goal is to assess Overall Survival (OS) of subjects treated with the Xoft Axxent Electronic Brachytherapy (eBx)® System when used for single-fraction, intra-operative radiation therapy (IORT) following maximal safe neurosurgical resection of recurrent glioblastoma for patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patients treated with Xoft IORT device median overall survival (OS)</measure>
    <time_frame>Overall Survival (OS) will be defined as the interval from enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to three years.</time_frame>
    <description>The median and mean OS with Xoft will be calculated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local Progression-free Survival (PFS)</measure>
    <time_frame>LocPFS will be assessed at baseline, Month 2, Month 6, then every 6 months until Year 3 follow-up.</time_frame>
    <description>Local PFS will be assessed at following intra-operative treatment with the Xoft Axxent Electronic Brachytherapy System following maximal safe neurosurgical resection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessment (Fact-Br)</measure>
    <time_frame>QOL will be assessed at baseline, Month 2, Month 6, then every 6 months until Year 3 follow-up.</time_frame>
    <description>To assess Quality of Life Status at baseline and following intra-operative treatment with the Xoft Axxent Electronic Brachytherapy System following maximal safe neurosurgical resection. The FACT-Br questionnaire assesses subjects on a scale of 0 (minimum) to 4 (maximum), 0 equal to &quot;Not at all&quot; and 4 equal to &quot;Very Much&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karnofsky Performance Status (KPS)</measure>
    <time_frame>KPS will be assessed at baseline, Month 2, Month 6, then every 6 months until Year 3 follow-up.</time_frame>
    <description>To assess Karnofsky Performance Status at baseline and following intra-operative treatment with the Xoft Axxent Electronic Brachytherapy System following maximal safe neurosurgical resection. The KPS grades from 100 to 0. 0, the lower score the worst the survival for the most serious illness. 100, the higher score, survival close to normal limits, no complaints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation-related Neurotoxicity</measure>
    <time_frame>Radiation-related Neurotoxicity will be assessed at baseline, Month 2, Month 6, then every 6 months until Year 3 follow-up.</time_frame>
    <description>Assess the rate of radiation-related neurotoxicity in subjects treated with the Xoft Axxent electronic Brachytherapy System when used for single-fraction, intra-operative radiation therapy treatment following maximal safe neurosurgical resection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate and severity of Adverse Events (AEs), Adverse Device Effects (ADEs), and Unanticipated Adverse Device Effects (UADEs)</measure>
    <time_frame>UADEs will be assessed at baseline, Month 2, Month 6, then every 6 months until Year 3 follow-up.</time_frame>
    <description>The rate and severity of Adverse Events (AEs), Adverse Device Effects (ADEs), and Unanticipated Adverse Device Effects (UADEs) will be assessed at the time of treatment and at all follow-up visits. All Grade 3 or higher adverse events will be followed until resolution. Each event will be classified according to:&#xD;
Device Related&#xD;
Procedure Related&#xD;
Radiation Related</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Glioblastoma</condition>
  <condition>GBM</condition>
  <condition>Recurrent GBM</condition>
  <arm_group>
    <arm_group_label>Intra-operative Radiation Therapy - IORT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-operative Radiation Therapy - IORT</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intra-operative Radiation Therapy - IORT</intervention_name>
    <description>Single dose of 20 Gy</description>
    <arm_group_label>Intra-operative Radiation Therapy - IORT</arm_group_label>
    <other_name>Electronic Brachytherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Potentially-resectable, histologically proven recurrent GBM&#xD;
&#xD;
          2. Subject must be ≥ 18 years of age&#xD;
&#xD;
          3. Subject must have a Karnofsky Performance Score ≥ 70%&#xD;
&#xD;
          4. Subject must have had a T1 weighted 3D MRI with Gadolinium enhancement within fourteen&#xD;
             (14) days prior to surgery&#xD;
&#xD;
          5. Women of child-bearing potential must have a negative pregnancy test within one week&#xD;
             of IORT treatment&#xD;
&#xD;
          6. Subjects of child-bearing potential must agree to use adequate contraceptive&#xD;
             precautions and not to breastfeed (if applicable)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. More than three relapses&#xD;
&#xD;
          2. Subject has multi-centric disease&#xD;
&#xD;
          3. Subject has tumors in or near (less than 10mm from tumor margin) critical brain&#xD;
             structures, that would exclude sufficient dose delivery to the tumor: such as:&#xD;
&#xD;
               1. Optic Chiasm&#xD;
&#xD;
               2. Optic Nerve&#xD;
&#xD;
          4. Women who are pregnant or nursing. Women with child-bearing potential or sexually&#xD;
             active men that are not willing/able to use medically acceptable forms of&#xD;
             contraception&#xD;
&#xD;
          5. Subject has contraindications for MRI with or without gadolinium injections&#xD;
&#xD;
          6. Subject has contraindications for anesthesia or surgery&#xD;
&#xD;
          7. Subject is on another therapeutic clinical trial concurrently&#xD;
&#xD;
          8. Subject had previous radiation for GBM less than 3 month earlier&#xD;
&#xD;
          9. Prior history of standard dose of Central Nervous System (CNS) of more than 60 Gy&#xD;
&#xD;
        Intra-Operative Exclusion Criteria&#xD;
&#xD;
          1. Frozen section does not show any sign of malignant tissue&#xD;
&#xD;
          2. Dose at any organ at risk will exceed 10 Gy including:&#xD;
&#xD;
               1. Chiasm&#xD;
&#xD;
               2. Optic Nerve&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A Wiles, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southeastern Spine &amp; Neurosurgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Research Coordinator</last_name>
    <phone>423-493-1667</phone>
    <email>donna.howard@hcahealthcare.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Donna O Howard</last_name>
    <phone>423-493-1667</phone>
    <email>donna.howard@hcahealthcare.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Southeastern Spine Neurosurgery</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David A Wiles, MD</last_name>
      <phone>423-693-2175</phone>
    </contact>
    <contact_backup>
      <last_name>Donna O Howard, RT(T)</last_name>
      <phone>423-493-1667</phone>
      <email>donna.howard@hcahealthcare.com</email>
    </contact_backup>
    <investigator>
      <last_name>David A. Wiles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nitesh Rana, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/2542195</url>
    <description>Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/1512163</url>
    <description>Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment.</description>
  </link>
  <link>
    <url>https://doi.org/10.3171/jns.1986.65.5.0654</url>
    <description>Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas</description>
  </link>
  <link>
    <url>http://doi.org/10.1016/j.jnci.2016.07.001</url>
    <description>Management of glioblastoma after recurrence: A changing paradigm.</description>
  </link>
  <link>
    <url>http://doi.org/10.17116/neiro20178135-16</url>
    <description>The Phenomenon of Long-Term Survival in Glioblastoma Patients. Part I: The Role of Clinical and Demographic Factors and an IDH1 Mutation</description>
  </link>
  <link>
    <url>http://doi.org/10.3390/brainsci8010005</url>
    <description>Extent of resection in newly diagnosed glioblastoma: Impact of a specialized neuro-oncology care center.</description>
  </link>
  <link>
    <url>https://www.frontiersin.org/article/10.3389/fneur.2012.00140</url>
    <description>The Value of Glioma Extent of Resection in the Modern Neurosurgical Era</description>
  </link>
  <link>
    <url>http://doi.org/10.1007/s00401-016-1545-1</url>
    <description>The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary</description>
  </link>
  <link>
    <url>http://doi.org/10.1016/S1470-2045(17)30194-8</url>
    <description>European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.</description>
  </link>
  <link>
    <url>http://doi.org/10.1007/s11060-017-2564-z</url>
    <description>Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis</description>
  </link>
  <link>
    <url>http://doi.org/10.1093/neuonc/nov145</url>
    <description>Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/8115886</url>
    <description>Retreatment of intracranial gliomas</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/2827051</url>
    <description>Reoperation in the treatment of recurrent intracranial malignant gliomas.</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/2827052</url>
    <description>Reoperation for recurrent glioblastoma and anaplastic astrocytoma.</description>
  </link>
  <link>
    <url>http://doi.org/10.1016/j.meddos.2010.08.001</url>
    <description>Novel Use of the Contura for High Dose Rate Cranial Brachytherapy</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/22582564.</url>
    <description>Polymodal therapy for high grade gliomas: a case report of favourable outcomes following intraoperative radiation therapy.</description>
  </link>
  <reference>
    <citation>Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1405-9.</citation>
    <PMID>2542195</PMID>
  </reference>
  <reference>
    <citation>Gaspar LE, Fisher BJ, Macdonald DR, LeBer DV, Halperin EC, Schold SC Jr, Cairncross JG. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys. 1992;24(1):55-7.</citation>
    <PMID>1512163</PMID>
  </reference>
  <reference>
    <citation>Choucair AK, Levin VA, Gutin PH, Davis RL, Silver P, Edwards MS, Wilson CB. Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg. 1986 Nov;65(5):654-8.</citation>
    <PMID>3021931</PMID>
  </reference>
  <reference>
    <citation>Mallick S, Benson R, Hakim A, Rath GK. Management of glioblastoma after recurrence: A changing paradigm. J Egypt Natl Canc Inst. 2016 Dec;28(4):199-210. doi: 10.1016/j.jnci.2016.07.001. Epub 2016 Jul 28. Review.</citation>
    <PMID>27476474</PMID>
  </reference>
  <reference>
    <citation>Goryaynov SA, Gol'dberg MF, Golanov AV, Zolotova SV, Shishkina LV, Ryzhova MV, Pitskhelauri DI, Zhukov VY, Usachev DY, Belyaev AY, Kondrashov AV, Shurkhay VA, Potapov AA. [The phenomenon of long-term survival in glioblastoma patients. Part I: the role of clinical and demographic factors and an IDH1 mutation (R 132 H)]. Zh Vopr Neirokhir Im N N Burdenko. 2017;81(3):5-16. doi: 10.17116/neiro20178135-16. Russian.</citation>
    <PMID>28665384</PMID>
  </reference>
  <reference>
    <citation>Haj A, Doenitz C, Schebesch KM, Ehrensberger D, Hau P, Putnik K, Riemenschneider MJ, Wendl C, Gerken M, Pukrop T, Brawanski A, Proescholdt MA. Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center. Brain Sci. 2017 Dec 25;8(1). pii: E5. doi: 10.3390/brainsci8010005.</citation>
    <PMID>29295569</PMID>
  </reference>
  <reference>
    <citation>Hardesty DA, Sanai N. The value of glioma extent of resection in the modern neurosurgical era. Front Neurol. 2012 Oct 18;3:140. doi: 10.3389/fneur.2012.00140. eCollection 2012.</citation>
    <PMID>23087667</PMID>
  </reference>
  <reference>
    <citation>Krivoshapkin A, Sergeev G, Gaytan A, Kurbatov V, Kiselev R, Kalneus L. Effect of pre- and postoperative tumor volumetric parameters on the life expectancy of patients with brain glioblastomas. Bull Neurol Psychiatry Neurosurg. 2016;6:59-67.</citation>
  </reference>
  <reference>
    <citation>Krivoshapkin AL, Sergeev GS, Gaytan AS, Kurbatov VP, Kalneus LE, Tarantsev EG. [New software for objective evaluation of brain glioblastoma resection degree]. Zh Vopr Neirokhir Im N N Burdenko. 2014;78(5):33-9; discussion 40. English, Russian.</citation>
    <PMID>25406906</PMID>
  </reference>
  <reference>
    <citation>Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016 Jun;131(6):803-20. doi: 10.1007/s00401-016-1545-1. Epub 2016 May 9. Review.</citation>
    <PMID>27157931</PMID>
  </reference>
  <reference>
    <citation>Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Le Rhun E, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger G, Soffietti R, Wick W; European Association for Neuro-Oncology (EANO) Task Force on Gliomas. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017 Jun;18(6):e315-e329. doi: 10.1016/S1470-2045(17)30194-8. Epub 2017 May 5. Review. Erratum in: Lancet Oncol. 2017 Nov;18(11):e642.</citation>
    <PMID>28483413</PMID>
  </reference>
  <reference>
    <citation>van Linde ME, Brahm CG, de Witt Hamer PC, Reijneveld JC, Bruynzeel AME, Vandertop WP, van de Ven PM, Wagemakers M, van der Weide HL, Enting RH, Walenkamp AME, Verheul HMW. Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis. J Neurooncol. 2017 Oct;135(1):183-192. doi: 10.1007/s11060-017-2564-z. Epub 2017 Jul 20.</citation>
    <PMID>28730289</PMID>
  </reference>
  <reference>
    <citation>Ringel F, Pape H, Sabel M, Krex D, Bock HC, Misch M, Weyerbrock A, Westermaier T, Senft C, Schucht P, Meyer B, Simon M; SN1 study group. Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection. Neuro Oncol. 2016 Jan;18(1):96-104. doi: 10.1093/neuonc/nov145. Epub 2015 Aug 4.</citation>
    <PMID>26243790</PMID>
  </reference>
  <reference>
    <citation>Landy HJ, Feun L, Schwade JG, Snodgrass S, Lu Y, Gutman F. Retreatment of intracranial gliomas. South Med J. 1994 Feb;87(2):211-4. Review.</citation>
    <PMID>8115886</PMID>
  </reference>
  <reference>
    <citation>Ammirati M, Galicich JH, Arbit E, Liao Y. Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery. 1987 Nov;21(5):607-14.</citation>
    <PMID>2827051</PMID>
  </reference>
  <reference>
    <citation>Harsh GR 4th, Levin VA, Gutin PH, Seager M, Silver P, Wilson CB. Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery. 1987 Nov;21(5):615-21.</citation>
    <PMID>2827052</PMID>
  </reference>
  <reference>
    <citation>Pace A, Dirven L, Koekkoek JAF, Golla H, Fleming J, Rudà R, Marosi C, Le Rhun E, Grant R, Oliver K, Oberg I, Bulbeck HJ, Rooney AG, Henriksson R, Pasman HRW, Oberndorfer S, Weller M, Taphoorn MJB; European Association of Neuro-Oncology palliative care task force. European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. Lancet Oncol. 2017 Jun;18(6):e330-e340. doi: 10.1016/S1470-2045(17)30345-5. Review.</citation>
    <PMID>28593859</PMID>
  </reference>
  <reference>
    <citation>Lederman G, Wronski M, Arbit E, Odaimi M, Wertheim S, Lombardi E, Wrzolek M. Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol. 2000 Apr;23(2):155-9.</citation>
    <PMID>10776976</PMID>
  </reference>
  <reference>
    <citation>Young B, Oldfield EH, Markesbery WR, Haack D, Tibbs PA, McCombs P, Chin HW, Maruyama Y, Meacham WF. Reoperation for glioblastoma. J Neurosurg. 1981 Dec;55(6):917-21.</citation>
    <PMID>6271933</PMID>
  </reference>
  <reference>
    <citation>Bloch O, Han SJ, Cha S, Sun MZ, Aghi MK, McDermott MW, Berger MS, Parsa AT. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J Neurosurg. 2012 Dec;117(6):1032-8. doi: 10.3171/2012.9.JNS12504. Epub 2012 Oct 5.</citation>
    <PMID>23039151</PMID>
  </reference>
  <reference>
    <citation>Ruben JD, Dally M, Bailey M, Smith R, McLean CA, Fedele P. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):499-508. Epub 2006 Mar 6.</citation>
    <PMID>16517093</PMID>
  </reference>
  <reference>
    <citation>Miyatake S, Nonoguchi N, Furuse M, Yoritsune E, Miyata T, Kawabata S, Kuroiwa T. Pathophysiology, diagnosis, and treatment of radiation necrosis in the brain. Neurol Med Chir (Tokyo). 2015;55(1):50-9. doi: 10.2176/nmc.ra.2014-0188. Epub 2014 Dec 20. Review.</citation>
    <PMID>25744350</PMID>
  </reference>
  <reference>
    <citation>Nguyen D, Rwigema JC, Yu VY, Kaprealian T, Kupelian P, Selch M, Lee P, Low DA, Sheng K. Feasibility of extreme dose escalation for glioblastoma multiforme using 4π radiotherapy. Radiat Oncol. 2014 Nov 7;9:239. doi: 10.1186/s13014-014-0239-x.</citation>
    <PMID>25377756</PMID>
  </reference>
  <reference>
    <citation>Veldwijk MR, Zhang B, Wenz F, Herskind C. The biological effect of large single doses: a possible role for non-targeted effects in cell inactivation. PLoS One. 2014 Jan 22;9(1):e84991. doi: 10.1371/journal.pone.0084991. eCollection 2014.</citation>
    <PMID>24465461</PMID>
  </reference>
  <reference>
    <citation>Herskind C, Wenz F. Radiobiological aspects of intraoperative tumour-bed irradiation with low-energy X-rays (LEX-IORT). Transl Cancer Res. 2014;3(1):3-17. doi:10.3978/j.issn.2218-676X.2014.01.06.</citation>
  </reference>
  <reference>
    <citation>Bensaleh S, Bezak E, Borg M. Review of MammoSite brachytherapy: advantages, disadvantages and clinical outcomes. Acta Oncol. 2009;48(4):487-94. doi: 10.1080/02841860802537916. Review.</citation>
    <PMID>19031175</PMID>
  </reference>
  <reference>
    <citation>Davis ME. Glioblastoma: Overview of Disease and Treatment. Clin J Oncol Nurs. 2016 Oct 1;20(5 Suppl):S2-8. doi: 10.1188/16.CJON.S1.2-8. Review.</citation>
    <PMID>27668386</PMID>
  </reference>
  <reference>
    <citation>Martínez-Garcia M, Álvarez-Linera J, Carrato C, Ley L, Luque R, Maldonado X, Martínez-Aguillo M, Navarro LM, Vaz-Salgado MA, Gil-Gil M. SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017). Clin Transl Oncol. 2018 Jan;20(1):22-28. doi: 10.1007/s12094-017-1763-6. Epub 2017 Oct 30.</citation>
    <PMID>29086250</PMID>
  </reference>
  <reference>
    <citation>Stupp R, Tonn JC, Brada M, Pentheroudakis G; ESMO Guidelines Working Group. High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010 May;21 Suppl 5:v190-3. doi: 10.1093/annonc/mdq187.</citation>
    <PMID>20555079</PMID>
  </reference>
  <reference>
    <citation>Scanderbeg DJ, Alksne JF, Lawson JD, Murphy KT. Novel use of the Contura for high dose rate cranial brachytherapy. Med Dosim. 2011 Winter;36(4):344-6. doi: 10.1016/j.meddos.2010.08.001. Epub 2010 Dec 8.</citation>
    <PMID>21144735</PMID>
  </reference>
  <reference>
    <citation>Zamzuri I, Rahman GI, Muzaimi M, Jafri AM, Nik Ruzman NI, Lutfi YA, Biswal BM, Nazaruddin HW, Mar W. Polymodal therapy for high grade gliomas: a case report of favourable outcomes following intraoperative radiation therapy. Med J Malaysia. 2012 Feb;67(1):121-2.</citation>
    <PMID>22582564</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <keyword>GBM</keyword>
  <keyword>Recurrent GBM</keyword>
  <keyword>Recurrent Glioblastoma</keyword>
  <keyword>IORT</keyword>
  <keyword>Intra-Operative Radiation Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

